3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
20
CNS
2
Tumor-Agnostic
1
Endocrine
1
Breast
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
Everolimus
23
pasireotide
14
lutetium Lu 177 dotatate
10
Octreotide
10
lanreotide
9
surufatinib
8
Carboplatin
8
Paclitaxel
7
pembrolizumab
5
amino-acid, glucose, and electrolyte solution
5
Thyrotropin Alfa
5
Sunitinib
5
Nivolumab
5
Injections
5
3-Iodobenzylguanidine
5
relacorilant
4
fosbretabulin
4
Temozolomide
4
Fulvestrant
4
Etoposide
4
Data Collection
4
Cisplatin
4
vandetanib
3
selpercatinib
3
dabrafenib
3
anlotinib
3
Mifepristone
3
Lutetium-177
3
Lutetium
3
Irinotecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
belzutifan
×
Endocrine
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA